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Abstract
Abnormal hyperphosphorylation of microtubule-associated protein tau plays a crucial role in neurodegeneration in
Alzheimer’s disease (AD). The aggregation of hyperphosphorylated tau into neurofibrillary tangles is also a hallmark brain
lesion of AD. Tau phosphorylation is regulated by tau kinases, tau phosphatases, and O-GlcNAcylation, a posttranslational
modification of proteins on the serine or threonine residues with b-N-acetylglucosamine (GlcNAc). O-GlcNAcylation is
dynamically regulated by O-GlcNAc transferase, the enzyme catalyzing the transfer of GlcNAc to proteins, and N-
acetylglucosaminidase (OGA), the enzyme catalyzing the removal of GlcNAc from proteins. Thiamet-G is a recently
synthesized potent OGA inhibitor, and initial studies suggest it can influence O-GlcNAc levels in the brain, allowing OGA
inhibition to be a potential route to altering disease progression in AD. In this study, we injected thiamet-G into the lateral
ventricle of mice to increase O-GlcNAcylation of proteins and investigated the resulting effects on site-specific tau
phosphorylation. We found that acute thiamet-G treatment led to a decrease in tau phosphorylation at Thr181, Thr212,
Ser214, Ser262/Ser356, Ser404 and Ser409, and an increase in tau phosphorylation at Ser199, Ser202, Ser396 and Ser422 in
the mouse brain. Investigation of the major tau kinases showed that acute delivery of a high dose of thiamet-G into the
brain also led to a marked activation of glycogen synthase kinase-3b (GSK-3b), possibly as a consequence of down-
regulation of its upstream regulating kinase, AKT. However, the elevation of tau phosphorylation at the sites above was not
observed and GSK-3b was not activated in cultured adult hippocampal progenitor cells or in PC12 cells after thiamet-G
treatment. These results suggest that acute high-dose thiamet-G injection can not only directly antagonize tau
phosphorylation, but also stimulate GSK-3b activity, with the downstream consequence being site-specific, bi-directional
regulation of tau phosphorylation in the mammalian brain.
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Introduction
Microtubule-associated protein tau is a cytosolic protein that
stimulates microtubule assembly and stabilizes microtubule
structure. The integrity of the microtubule system is essential for
the transport of materials between the cell body and synaptic
terminals of neurons. The microtubule system is disrupted and
replaced by the accumulation of highly phosphorylated tau as
neurofibrillary tangles in affected neurons in the brains of
individuals with Alzheimer disease (AD) and other neurodegen-
erative disorders collectively called tauopathies. Neurofibrillary
tangles are also one of the hallmark histopathological lesions of AD
brain. Many studies have demonstrated the critical role of
hyperphosphorylation and aggregation of tau in neurodegenera-
tion in AD and other tauopathies. The abnormal hyperpho-
sphorylation may cause dissociation of tau from microtubules and,
consequently, raise intracellular tau concentration enough to
initiate its polymerization into neurofibrillary tangles [1].
The mechanisms by which tau becomes abnormally hyperpho-
sphorylated in AD and other tauopathies are not well understood.
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phosphorylation is mainly controlled by the kinases glycogen
synthase kinase-3b (GSK-3b) and cyclin-dependent protein kinase
5 (cdk5) [2,3,4,5] as well as protein phosphatase 2A (PP2A)
[6,7,8,9,10]. A down-regulation of PP2A in AD brain was found
by our and other groups [9,11,12,13,14], suggesting that this
decrease may be partially responsible for the abnormal hyperpho-
sphorylation of tau in AD.
It was demonstrated recently that tau phosphorylation is
negatively regulated by O-GlcNAcylation, a posttranslational
modification of proteins with b-N-acetylglucosamine (GlcNAc)
[15,16,17,18,19]. Like protein phosphorylation, O-GlcNAcylation
is dynamically regulated by O-GlcNAc transferase (OGT), the
enzyme catalyzing the transfer of GlcNAc from UDP-GlcNAc
donor onto proteins, and N-acetylglucosaminidase (OGA), the
enzyme catalyzing the removal of GlcNAc from proteins [20].
Global O-GlcNAcylation and specifically tau O-GlcNAcylation is
decreased in AD brain [19]. These observations suggest that
decreased brain glucose metabolism may promote abnormal
hyperphosphorylation of tau via down-regulation of O-GlcNAcy-
lation, a sensor of intracellular glucose metabolism [21]. However,
tau is abnormally hyperphosphorylated at multiple phosphoryla-
tion sites and phosphorylation at various sites has different impacts
on tau function and pathology [22]. How O-GlcNAcylation affects
site-specific tau phosphorylation in vivo is not well understood
[23].
In this study, we injected a highly selective OGA inhibitor,
thiamet-G, into the lateral ventricle of mice to increase O-
GlcNAcylation of proteins and investigated alterations of site-
specific tau phosphorylation. We found that acute high-dose
thiamet-G treatment led to decreased phosphorylation at some
sites but increased phosphorylation at other sites of tau in the
brain. We further investigated possible underlying mechanisms for
these differential effects.
Materials and Methods
Antibodies and Reagents
The primary antibodies used in this study are listed in Table 1.
Peroxidase-conjugated anti-mouse and anti-rabbit IgG were
obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). The enhanced chemiluminescence (ECL) kit
was from Amersham Pharmacia (Piscataway, NJ, USA). Thiamet-
G was synthesized as described previously [23]. Other chemicals
were from Sigma (St. Louis, MO, USA).
Animals and Intracerebroventricular (icv) Injection
Thirty transgenic (Tg) mice (male, ,6 months old) that express
the largest isoform of wild-type human tau, tau441, were used in
this study. The transgenic mice [24] were originally from Dr. A.
Takashima of the Riken Brain Science Institute, Saitama, Japan,
and were bred in our institute’s animal colony. The mice were
housed in a temperature-controlled room and fed standard rodent
food pellets and water. The use of animals was in accordance with
the guidelines of the National Institutes of Health and was
approved by the Animal Welfare Committee of the New York
State Institute for Basic Research in Developmental Disabilities.
Mice were first anesthetized by an intraperitoneal injection of
0.3% sodium pentobarbital (40 mg/kg). Thiamet-G (2.5 mlo f
35 mg/ml) dissolved in 0.9% NaCl was injected bilaterally into the
lateral ventricles of the brains at a dose of 175 mg/mouse, which
correlated to a final concentration of approximately 700 mM in the
brain, assuming a combined brain and spinal cord volume of
900 mL. The same volume of 0.9% NaCl alone was injected in
control mice. The stereotaxic coordinates for the icv injection
were: 0.4 mm anterior to posterior Bregma, 1.0 mm mid to
lateral, and 2.2 mm dorsal to ventral dura. Mice were euthanized
by cervical dislocation 4.5 h, 9 h or 24 h after icv injection
(Fig. 1A). Anesthesia was not used to sacrifice mice because it
affects tau phosphorylation [25,26]. The brains were removed and
stored at 280uC immediately for processing at a later time.
Western Blot Analysis
The left hemispheres of the mouse brains were homogenized in
pre-chilled buffer containing 50 mM tris-HCl (pH7.4), 8.5%
sucrose, 10 mM b- mercaptoethanol, 1.0 mM EGTA, 1.0 mM
phenyl-methylsulfonyl fluoride, 2.0 mg/ml aprotinin, 25 mg/ml
leupeptin, and 1.0 mg/ml pepstatin. Protein concentrations of the
homogenates were determined by modified Lowry method [27].
The samples were resolved in 10% SDS-PAGE and electro-
transferred onto Immobilon-P membrane (Millipore, Bedford,
MA, USA). The blots were then probed with primary antibodies
and developed with the corresponding horseradish peroxidase–
conjugated secondary antibody and enhanced chemiluminescence
kit (Pierce, Rockford, IL, USA). Densitometric quantification of
protein bands in Western blots was analyzed by using TINA
software (Raytest IsotopenmeBgerate GmbH, Straubenhardt,
Germany). Quantitative comparisons were analyzed by using
student t-test, and the differences between groups were regarded to
be significant when p,0.05.
Culture of Adult Hippocampal Progenitor (AHP) Cells and
PC12 cells
Neuronal progenitor cells were isolated from the hippocampus
of adult Wistar rats (Charles River Laboratories, Wilmington, MA,
USA) and cultured in neurobasal A medium consisting of 2% B27,
0.5 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml strep-
tomycin, and 10 ng/ml fibroblast growth factor-2 (FGF-2) at 37uC
in a humidified 5% CO2 atmosphere, as described previously [28].
The medium was routinely changed every another day. When the
cells reached ,80% confluence, they were treated with 20 nM
thiamet-G for 0.5–24 hr. At the end of the treatments, the cells
were washed with PBS three times and then lysed by using
Lammlie SDS-gel sample buffer that also contained 50 mM NaF,
1.0 mM Na3VO4, 1.0 mM phenyl-methylsulfonyl fluoride,
2.0 mg/ml aprotinin, 25 mg/ml leupeptin and 1.0 mg/ml pepsta-
tin.
Differentiated AHP cells were also used in this study. The AHP
cells were differentiated by replacing FGF-2 with 5 mM retinoic
acid and 10% fetal calf serum when the cells reached
approximately 80% confluency. The neuronal cultures were
treated with 20 nM thiamet-G after 5–7 days of growth in the
differentiation medium. At this stage, approximately 80% of the
cells expressed the neuronal markers bIII-tubulin and microtu-
bule-associated protein 2, and less than 5% expressed the astroglial
marker Glial fibrillary acidic protein or the oligodendrocyte
marker O4 (data not shown).
PC12 cells that stably express the largest isoform of human
brain tau, tau441, were generated as described [16]. The cells were
differentiated with 50 ng/ml nerve growth factor for 6 days before
treatment with thiamet-G.
Statistical analyses
Where appropriate, the data are presented as mean 6 SEM.
One-way ANOVA and post hoc analyses were performed using
the scientific statistic software Graph Pad Prism 4 (San Diego, CA,
USA). p,0.05 was considered to be statistically significant.
Effects of Thiamet-G on Tau Phosphorylation
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Thiamet-G increases protein O-GlcNAcylation level in the
brain
To investigate the effects of thiamet-G on tau phosphorylation
at multiple phosphorylation sites in vivo, we first confirmed the
elevation of protein O-GlcNAcylation level of the brains of tau Tg
mice after icv injection of the drug. We observed a time-dependent
elevation of O-GlcNAcylation after thiamet-G treatment, as
determined by Western blots developed with monoclonal antibody
RL2 toward O-GlcNAc (Fig. 1B). A marked increase in O-
GlcNAcylation of numerous proteins at the range from 50-kDa to
larger than 220 kDa was seen. Quantification of these RL2
positive bands indicated a 5-fold increase in global O-GlcNAcyla-
tion 4.5 h after thiamet-G injection and a 10-fold increase 24 h
after injection (Fig. 1C). These results indicate a marked increase
in O-GlcNAcylation in the mouse brains after Tiamet-G injection.
Thiamet-G induces site-specific changes of tau
phosphorylation in the mouse brain
We then studied alterations of tau phosphorylation at individual
phosphorylation sites in the mouse brains after treatment with
thiamet-G by using Western blots developed with a battery of
phosphorylation-dependent and site-specific tau antibodies. Anti-
body 92e toward total tau in a phosphorylation-independent
manner was also included to check whether there was any change
in the total tau level. We found that thiamet-G did not alter tau
level in the mouse brain, but led to site-specific, bi-directional
changes of tau phosphorylation (Fig. 2). Along with the marked
increase in O-GlcNAcylation after thiamet-G treatment, we
observed decreased tau phosphorylation at Thr181, Thr212,
Ser214, Ser262/Ser356, Ser404 and Ser409. In contrast, tau
phosphorylation was increased instead at some other sites such as
Ser199, Ser202, Ser396 and Ser422 upon thiamet-G treatment.
Among the 12 phosphorylation sites studied, tau phosphorylation
at only one site (Thr217) was not significantly changed upon
thiamet-G treatment. Whereas the alterations of tau phosphory-
lation at Thr205 was found to be bi-directional, with a decrease
4.5 h after thiamet-G injection and an increase 9 and 24 h after
thiamet-G injection. These results indicate that the effects of
thiamet-G–induced tau phosphorylation are not only dynamic,
but also site-specific and bidirectional.
Thiamet-G induces activation of GSK-3b in the mouse
brain
Negative regulation of phosphorylation by O-GlcNAcylation of
tau has been observed previously [15,16,18,19,23]. To investigate
why tau phosphorylation at Ser199, Ser202, Ser396 and Ser422
was increased when O-GlcNAcylation was elevated upon thiamet-
G treatment, we studied the major tau kinases. We first studied
GSK-3b and its upstream regulating pathway, the PI3K-AKT
signaling pathway. GSK-3b activity is mainly regulated negatively
via its phosphorylation at Ser9 by AKT, which in turn is regulated
by PI3K and other factors [29]. We found that thiamet-G
Table 1. Primary antibodies employed in this study.
Antibody Type Specificity Phosphorylation sites Reference/Source
RL2 Mono- O-GlcNAc Affinity Bioreagents, Golden, CO, USA
92e Poly- Tau [44]
pT188 Poly- P-tau Thr181 Invitrogen, Carlsbad, CA, USA
pS199 Poly- P-tau Ser199 Invitrogen
pS202 Poly- P-tau Ser202 Invitrogen
pT205 Poly- P-tau Thr205 Invitrogen
pT212 Poly- P-tau Thr212 Invitrogen
pS214 Poly- P-tau Ser214 Invitrogen
pT217 Poly- P-tau Thr217 Invitrogen
pS262 Poly- P-tau Ser262 Invitrogen
pS356 Poly- P-tau Ser356 Invitrogen
pS396 Poly- P-tau Ser396 Invitrogen
pS404 Poly- P-tau Ser404 Invitrogen
pS409 Poly- P-tau Ser409 Invitrogen
pS422 (R145) Poly- P-tau Ser422 [44]
Anti-p-GSK-3b Poly- P-GSK-3b Ser9 Cell Signaling Technology, MA, USA
Anti-p-GSK-3b Poly- P-GSK-3b Tyr216 Invitrogen
R133d Poly- GSK-3b [45]
Anti-p-AKT Poly- P-AKT Ser473 Cell Signaling Technology
Anti-AKT Poly- AKT Cell Signaling Technology
Anti-p-PI3K (85 kDa) Poly- P-PI3K (85 kDa) Tyr458/Tyr199 Cell Signaling Technology
Anti-PI3K (85 kDa) Poly- PI3K (85 kDa) Cell Signaling Technology
Anti-CDK5 Poly- CDK5 Santa Cruz Biotechnology, CA, USA
Anti-p35 Poly- p35 Santa Cruz Biotechnology
Anti-GAPDH Mono- GAPDH Santa Cruz Biotechnology
doi:10.1371/journal.pone.0035277.t001
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after treatment for 9–24 h, but blocked its phosphorylation at Ser9
completely (Fig. 3A), suggesting that GSK-3b was markedly
activated under these conditions. Phosphorylation of GSK-3b at
Tyr216, which makes it more active, was also increased 24 h after
thiamet-G treatment. Consistent with the almost complete
dephosphorylation of GSK-3b at Ser9, Ser473 and Thr308
phosphorylation of AKT, which determines its kinase activity, was
also blocked by thiamet-G treatment. However, we did not find
any significant changes of either the level or the activation of
PI3K, the major upstream kinase of AKT, in the mouse brain after
thiamet-G treatment. These results suggest that thiamet-G
induced over-activation of GSK-3b via inhibition of AKT
phosphorylation. The over-activation of GSK-3b may explain
the increased tau phosphorylation at Ser199, Ser202, Ser396 and
Ser422, because these sites are the phosphorylation sites catalyzed
mainly by GSK-3b [30].
CDK5 is the second most important tau kinase in the brain [31]
and is activated by p35/p25. We thus also studied the level of
CDK5 and its activators. We found that thiamet-G did not alter
either CDK5 or p35 (Fig. 3). P25, which is the truncated and a
more active form of p35, was not detectable in the mouse brain.
Thiamet-G induces increased O-GlcNAcylation, but fails
to activate GSK3b or increase tau phosphorylation in
cultured neuronal cells
To elucidate the complex regulation of site-specific phosphor-
ylation induced by thiamet-G, we employed cultured cells, because
cell cultures are more easily manipulated. We first selected AHP
cells because they are more close to brain neurons than tumor cell
lines. As expected, treatment of AHP cells with 20 nM thiamet-G
increased protein O-GlcNAcylation (Fig. 4A). While we observed
decreased tau phosphorylation at several phosphorylation sites in
the AHP cells after thiamet-G treatment, it did not induce any
significant increase in tau phosphorylation at the phosphorylation
sites studied except at a transient elevation of Ser396 at 30 min
after the treatment (Fig. 4C, D). We then investigated the levels
and the activation of GSK-3b and the upstream PI3K-AKT
signaling transduction pathway, as well as CDK5/p35. We did not
find any significant changes upon the treatments with thiamet-G
Figure 1. Experimental design and effects of icv injection of thiamet-G on brain protein O-GlcNAcylation. (A) Diagram showing the
experimental design of icv injection. Thiamet-G (175 mg per mouse) was injected into the lateral ventricles of the brain, and then the tau Tg mice
were sacrificed 4.5 h, 9 h, or 24 h after injection. (B) The brain homogenates were analyzed by Western blots developed with monoclonal antibody
RL2 against O-GlcNAcylated proteins and, as a loading control, anti-GAPDH. (C) All of the RL2-positive bands in the blots were quantified
densitometrically, and the intensities of the total O-GlcNAcylated proteins after being normalized by the intensity of GAPDH are shown (mean 6 SEM;
n=5; *, p,0.05; **, p,0.01; ***, p,0.001 vs. saline controls).
doi:10.1371/journal.pone.0035277.g001
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conclusion above that the increased tau phosphorylation at some
sites observed in the thiamet-G treated mouse brains was due to
GSK3b activation.
To learn whether the phenomena we observed in undifferen-
tiated AHP cells were specific to these cells, we also performed
similar experiments in differentiated AHP cells and differentiated
PC12 cells. As seen in proliferating AHP cells, we did not observe
any marked elevation of tau phosphorylation at any phosphory-
lation sites or changes of tau kinases upon thiamet-G treatments in
these two types of cells (data not shown).
Figure 2. Levels of phosphorylation of tau at different sites in tau Tg mouse brains after icv injection of thiamet-G. (A) Western blots
of the brain homogenates developed with an antibody to total tau (92e) and a battery of phosphorylation-dependent and site-specific antibodies to
determine tau phosphorylation at individual phosphorylation sites, as indicated at the left side of the blots. (B–D) Levels of tau phosphorylation at
individual sites 4.5 h (B), 9 h (C), or 24 h (D) after injection were determined by densitometrical quantitation of the blots, as shown in A. Data (mean
6 SEM; n=5) are presented as percentage of saline control injection. The total tau level of each sample was used for normalization for calculation.
*p,0.05 vs. saline injection.
doi:10.1371/journal.pone.0035277.g002
Figure 3. Analyses of major tau kinases in tau Tg mouse brains after thiamet-G treatments. (A) Western blots of the brain homogenates
developed with antibodies indicated at the left side of the blots. GAPDH blot was included as a loading control. (B) The blots were quantified
densitometrically, and the immunoreactivities (mean 6 SEM; n=5) of the indicated phosphorylated kinases over that of the total kinase counterparts
are shown to represent the activation statuses of these kinases. Note that the GSK-3b(Y216) antibody also recognized GSK-3a (upper band in A). Only
the GSK-3b band (lower band) was used for quantification. In case of CDK and p35, GAPDH was used for normalization. *p,0.05 vs. saline injection.
doi:10.1371/journal.pone.0035277.g003
Effects of Thiamet-G on Tau Phosphorylation
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Thiamet-G is a highly specific OGA inhibitor that was
synthesized based on rationale design [23]. Initial studies indicated
that this compound reduce tau phosphorylation at some
phosphorylation sites that can be abnormally phosphorylated in
AD [23], suggesting that OGA inhibition may offer a potential
therapeutic approach for slowing tau-mediated neurodegeneration
seen in AD and other tauopathies. Because tau phosphorylation at
different sites has different impacts on tau’s function and pathology
[22], investigating the role of thiamet-G on site-specific tau
phosphorylation is needed. In this study we found that icv injection
of thiamet-G led to decreased tau phosphorylation at Thr181,
Thr212, Ser214, Ser262/Ser356, Ser404 and Ser409, but
increased tau phosphorylation at Ser199, Ser202, Ser396 and
Ser422 in the mouse brain.
We and other groups have previously shown that O-
GlcNAcylation regulates phosphorylation of tau in a reciprocal
manner overall [15,16,17,18,19,23]. Our observations of de-
creased tau phosphorylation at Thr181, Thr212, Ser214, Ser262/
Ser356, Ser404 and Ser409 are consistent with previous studies,
further supporting the reciprocal relationship between O-GlcNA-
cylation and phosphorylation of tau at these sites. To understand
the underlying mechanism by which thiamet-G increased tau
phosphorylation at some other phosphorylation sites in the mouse
brain, we investigated the effects of thiamet-G injection on the
major tau kinases. We found that thiamet-G at the dose injected
into the brain completely blocked Ser9 phosphorylation of GSK-
3b, indicating a marked activation of this major tau kinase. Our
previous studies have demonstrated that tau phosphorylation at
Ser199, Ser202 and Ser396 are mainly regulated by GSK-3b [30].
Taken together, we conclude that the elevation of tau phosphor-
ylation at Ser199, Ser202, Ser396 and Ser422 results from the
combinational effects of the increase in tau O-GlcNAcylation and
the activation of GSK-3b activity, and that GSK-3b activation
predominated and led to the net increase in tau phosphorylation at
these sites in the mouse brain. Our results showed that GSK-3b
was not activated in cultured neuronal cells treated with thiamet-
G, consistent with the absence of any increase in tau phosphor-
ylation at these phosphorylation sites. In a previous study, when
Figure 4. Effects of thiamet-G treatment on protein O-GlcNAcylation and tau phosphorylation in AHP cells. (A) Proliferating AHP cells
were treated with 20 nM thiamet-G for various periods of time, and the protein O-GlcNAcylation of the cell lysates was determined by Western blots
developed with RL-2 against O-GlcNAc. (B) The blots were quantified densitometrically, and the O-GlcNAc levels are presented as the percentage of
control cells at each time point. (C) Western blots developed with 92e for detecting total tau level and with several phosphorylation-dependent and
site-specific tau antibodies for detecting phosphorylation of tau at individual sites. (D) The tau blots were quantified densitometrically, and the tau
level and site specific phosphorylation level are presented as the percentage of control cells at each time point. The data shown are mean 6 SEM of
triplicates of one of three separate experiments with similar results.
doi:10.1371/journal.pone.0035277.g004
Effects of Thiamet-G on Tau Phosphorylation
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35277thiamet-G was administered to rats orally for 24 hrs, tau
phosphorylation at these sites was not found to be increased
[23]. Whether the discrepancy between this previous study and the
present study is due to different routes of drug administration (oral
vs. icv injection), the attainment of different doses within the brain,
or the use of different species (rat vs. mouse) is currently unknown.
It is possible that there is either a dose-dependent effect of thiamet-
G on GSK-3b–stimulation or an off target effect of thiamet-G
when used at high doses directly in the brain. Indeed, it is likely
that the icv injection of this study led to a much higher thiamet-G
concentration in the central nervous system than that from oral
dosing. Unfortunately, GSK-3b modification and activity in the
brain was not examined in the previous study, so direct
comparisons are not possible.
Our results indicated marked differences in the effects of
thiamet-G on tau phosphorylation between the mouse brains and
the cultured neurons. Further experiments indicated that thiamet-
G–induced increase of tau phosphorylation at several sites resulted
from activation of GSK-3b, a major tau kinase, but this activation
did not occur in cultured cells. Different regulations of tau
phosphorylation by extracellular signaling between the brains and
the cultured neurons might also contribute to the different results
we observed. A previous study has demonstrated that tau
phosphorylation is regulated by FGF-2 through GSK-3b [32].
Our observations of GSK-3b activation in the brains but not in the
cultured cells are consistent with this speculation. The mice we
used for this study expressed the wild-type human tau isoform.
Although we cannot absolutely rule out the possibility that the
different results between the mouse brains and the cell cultures
might also result from different tau species (mouse/human tau
versus rat tau), this possibility is very small, because our
observations that thiamet-G–induced GSK-3b activation in the
brains, but not in the cultured cells, can explain the different
results in these two systems nicely.
Our studies on the upstream regulating kinases of GSK-3b
suggest that thiamet-G led to marked GSK-3b activation as the
result of an inhibition of AKT by reducing its phosphorylation at
Ser473 and Thr 308, which regulates its activity positively [29].
AKT inhibition may also contribute to the thiamet-G–induced
decrease of tau phosphorylation at Thr212 and Ser214, because
these two sites are also substrates of AKT [33]. AKT
phosphorylation was mainly catalyzed by the mTORC2 complex
and PI3K–phosphoinositide-dependent protein kinase-1 (PDK1).
Because we did not observe the corresponding decrease in PI3K,
we speculate that the reduction/elimination of phosphorylation of
AKT and GSK-3b after thiamet-G treatment may result from
elevation of O-GlcNAcylation of AKT, PDK1 and/or mTOR.
Alternatively, it could be off-target effect of the inhibitor when
used at high doses. Phosphorylation of these kinases has been
reported to be regulated negatively by O-GlcNAcylation
[34,35,36,37]. It is worth noting that different effects of OGA
inhibition on phosphorylation of AKT and GSK-3 have been
reported. Elevation of O-GlcNAcylation in skeletal muscles after
OGA inhibition using another inhibitor, PUGNAc, does not
significantly alter insulin-stimulated phosphorylation of AKT or
GSK-3 [38]. In differentiated 3T3-L1 adipocytes, two different
OGA inhibitors have been found to increase O-GlcNAc levels but
not alter insulin-stimulated phosphorylation of AKT nor induce
insulin resistance either [39,40]. Therefore, it remains somewhat
unclear as to the effects of OGA inhibition on alteration of GSK-
3b levels and AKT activity; the effects observed here could stem
from high-dose inhibition of OGA, or alternatively from off-target
effects of using the inhibitor at a high dose.
Tau is abnormally hyperphosphorylated and aggregated in AD
and other tauopathies. Previous studies from our and other groups
have demonstrated differential roles of tau phosphorylation at
various phosphorylation sites. A quantitative in vitro study
demonstrated that phosphorylation of tau at Ser262, Thr231,
and Ser235 inhibits its binding to microtubules by ,35%, ,25%,
and ,10%, respectively [41]. In vitro kinetic studies of the binding
between hyperphosphorylated tau and normal tau suggest that
Ser199/Ser202/Thr205, Thr212, Thr231/Ser235, Ser262/
Ser356 and Ser422 are among the critical phosphorylation sites
that convert tau to an inhibitory molecule that sequesters normal
microtubule-associated proteins from microtubules [42]. Further
phosphorylation at Thr231, Ser396, and Ser422 promotes self-
aggregation of tau into filaments. It is obvious that tau
phosphorylation at various sites impacts tau activity and
aggregation collectively. Our recent study has demonstrated that
tau phosphorylation at the proline-rich region, which is located
upstream of the microtubule-binding domains, inhibits its
microtubule assembly activity moderately and promotes its self-
aggregation slightly. Tau phosphorylation at the C-terminal tail
region increases its activity and promotes its self-aggregation
markedly. Tau phosphorylation at both of these regions plus the
microtubule-binding region nearly diminishes its activity and
disrupts microtubules [43]. Therefore, the overall impacts of
thiamet-G on tau need to be further verified by its functional
studies, and testing the effects of thiamet-G on cognitive function
in mouse AD models, especially using different doses, becomes
urgent before considering it to be a therapeutic agent for treating
AD.
In conclusion, thiamet-G is a specific OGA inhibitor and is very
effective in elevating protein O-GlcNAcylation level in the
mammalian brain. Because thiamet-G not only directly modulated
tau phosphorylation inversely, but also stimulated GSK-3b activity
likely via inhibition of AKT, the final consequences were a
decrease in tau phosphorylation at Thr181, Thr212, Ser214,
Ser262/Ser356, Ser404 and Ser409, and an increased in tau
phosphorylation at Ser199, Ser202, Ser396 and Ser422 in the
brain after thiamet-G treatment. The site-specific, bi-directional
regulation of tau phosphorylation warrants further studies on
evaluation of dose and time dependent effects on OGA inhibition.
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